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Editorial

mTOR: Alzheimer’s disease prevention for APOE4 carriers
Ai-Ling Lin, David Allan Butterfield and Arlan Richardson
Alzheimer’s disease (AD) is the most common form
of dementia and the 6th leading cause of death in the US.
Inheritance of the Apolipoprotein ε4 (APOE4) allele is the
strongest genetic risk factor for late-onset AD - APOE4
carriers accumulate beta-amyloid (Aβ) and neurofibrillary
tau tangles earlier and with more extensive pathology
compared to non-carriers. However, decades before the
aggregation of Aβ and tau, cognitively normal APOE4
carriers have developed neurovascular deficits, including
reduced cerebral blood flow (CBF) and impaired bloodbrain barrier (BBB) integrity [1]. The above indicates
that brain physiology is altered in APOE4 carriers
before clinical markers such as Aβ, tau pathology, and
memory deficits appear, suggesting that vascular changes
predispose APOE4 carriers to developing AD. Therefore,
early interventions that can restore neurovascular deficits
to normal could be critical in potentially preventing
the development of AD-related neuropathology and
cognitive impairment. In a recent study, using magnetic
resonance imaging (MRI), Lin et al. reported that young,
asymptomatic APOE4 targeted-replacement mice treated
with rapamycin had restored CBF and BBB integrity
to the level of wild-type controls [2]. The preserved
vasculature was associated with amelioration of incipient
learning deficits of the APOE4 transgenic mice. The
significance of this discovery is that brain functions are
pharmacologically reversible and AD potentially could be
prevented in asymptomatic APOE4 carriers.
Rapamycin is a drug approved by US Food and Drug
Administration (FDA). It has been widely used in clinical
settings and was originally used as an immunosuppressive
agent to prevent rejection of organs in transplant patients.
By 1991, Heitman and co-workers discovered a kinase,
Target of Rapamyin (TOR) [3]. In mammals, the protein
is specified as mammalian TOR, or mTOR. mTOR is
the serine/threonine kinase that is the regulatory nexus
in the response of eukaryote cells to nutrients, growth
factors, and cellular energy status. Rapamycin is a mTOR
inhibitor. A major breakthrough occurred in 2009 when
it was shown that rapamycin, which reduced mTOR
signaling, increased the lifespan of mice (see review in
[4]). In addition, rapamycin has been shown to reduce
a variety of cancers in mice as well as atherosclerosis
in mouse models fed high fat diets as well as improve
immunity in elderly humans [5]. As regard to the human
central nervous system, several studies have shown that
inhibition of mTOR by rapamycin treatment improves
cognition, slows brain aging, and impedes the progress of
www.impactjournals.com/oncotarget

neurodegenerative disorders through pathways associated
with autophagy, glucose metabolism and mitochondrial
functions [6].
Lin et al. demonstrated that mTOR inhibition
reduced proinflammatory pathways in brain vasculature
that otherwise impair BBB integrity in the APOE4
transgenic mice [2]. Loss of BBB integrity is considered
one of the initiating events that lead to AD-like
pathological cascade in the APOE4 carriers [1]. Restoring
BBB integrity is highly associated with improved CBF
and preserved learning ability of the APOE4 transgenic
mice [2]. In addition, Lin et al. previously reported
that inhibition of mTOR activates endothelial nitric
oxide synthase and causes the release of nitric oxide, a
vasodilator, which in turn increases CBF [7]. In mice
modeling human AD (hAPP (J20)), Lin et al. found
that rapamycin restored their CBF and vascular density,
which were associated with reduced accumulation of Aβ
and cerebral amyloid angiopathy, and improved memory
[7]. Collectively, these findings indicate that rapamycin
alters neurovascular functions through multiple potential
pathways. Because neurovascular defects are one of the
earliest events that lead to AD-like pathology, mTOR
inhibition might be an effective intervention to preserve
brain vascular functions and consequently slow or prevent
the progress of AD development.
In conclusion, mTOR inhibition has been shown
to increase lifespan and healthspan in various species.
Rapamycin (or its derivatives, rapalogues) has been
approved by the FDA since 1999 for various uses in
humans, and these compounds have been given to cancer
patients for relatively long periods of time with little
change in the quality of life. Lin et al. further demonstrated
that rapamycin restores and preserves neurovascular
functions in the APOE4 transgenic mice using MRI. Their
results may provide the basis for future AD prevention
trials in human APOE4 carriers.
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